Lonza nominates Juan Andres and Eric Drapé as independent Board Members

Juan Andres, a Spanish national, has a career spanning more than 35 years during which he has held a variety of leadership positions. Most recently he was President, Strategic Partnerships and Enterprise Expansion at Moderna, where he led the technical development, scale-up and worldwide supply of its COVID-19 mRNA vaccine. Before joining Moderna, Juan held roles as Head of Technical Operations as well as Head of Quality at Novartis. Prior to that, he spent more than 15 years at Eli Lilly. Juan’s deep understanding of the pharma and biotech industry is complemented by international business expertise, having spent time in Puerto Rico, Spain, Switzerland, the UK and the US. Juan is a Board Member at Avantor.

Jean-Marc Huët, Board Chairman, LonzaI would like to take this chance to congratulate Juan and Eric on behalf of the Board for their nomination. Both nominees share extensive leadership experience, alongside diverse and complementary backgrounds that are well suited to Lonza today. Juan brings strong strategic capabilities, and both leaders bring deep manufacturing expertise that is highly relevant for our business. Juan and Eric know the CDMO industry well and have been customers of Lonza in the past. This fresh external perspective will bring valuable insights to support our focus on delivering innovation, operational excellence, and outstanding customer service.”

Source:

Lonza